Skip to content

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial of Fourteen Day Treatment With Lansoprazole 15 mg or 30 mg Once a Day in Frequent Nighttime Heartburn

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00701259
Enrollment
852
Registered
2008-06-19
Start date
2007-01-31
Completion date
2007-08-31
Last updated
2010-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frequent Heartburn

Keywords

Frequent heartburn, proton pump inhibitor, lansoprazole, Treatment of, over 14 days

Brief summary

Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach. This study will investigate the safety and efficacy of lansoprazole 15 mg or 30 mg administered once a day in preventing frequent nighttime heartburn.

Interventions

DRUGLansoprazole

Lansoprazole 15 mg once per day for 14 days

DRUGplacebo

Sponsors

Novartis
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Experiencing heartburn at least 2 days per week during the nighttime period over the past month. * Having heartburn that responds to heartburn medication. * Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.

Exclusion criteria

* Having history of erosive esophagitis or gastroesophageal reflux disease diagnosed by a physician and confirmed by testing (endoscopy). * Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study. Other protocol-defined inclusion/

Design outcomes

Primary

MeasureTime frame
Percentage of nighttimes with no heartburn during 14 days of double-blind treatment in subjects with frequent heartburn.14 days

Secondary

MeasureTime frame
Proportion of 24 hour days with no heartburn during 14 days of treatment. Proportion of subjects with no heartburn during day 1 (the 24 hours following the first dose. The evaluation of lansoprazole safety.14 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026